Golidocitinib ameliorates radio-immunotherapy-induced lung injury by alleviating oxidative stress and Pyroptosis.
BACKGROUND The combination of radiotherapy and immunotherapy (iRT) is effective against lung cancer but increases the risk of pulmonary toxicity. This iRT-induced lung injury (iRT-LI) may lead to treatment interruption and consequently worsen clinical outcomes. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor,...